MedTrace Logo

Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication

NCT00375843 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2013-02-06

No results posted yet for this study

Summary

This study will examine how brain activity is affected by antidepressant treatment and how changes in brain activity relate to treatment response in people with depression.

Conditions

Interventions

DRUG

Escitalopram

Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.

DRUG

Sertraline

Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Ian Cook, MD · UCLA Semel Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2007-06-30
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375843 on ClinicalTrials.gov